{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:33:11Z","timestamp":1785799991283,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100013700","name":"National Comprehensive Cancer Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["N01-CM-2011-00039"],"award-info":[{"award-number":["N01-CM-2011-00039"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology"},{"name":"Susan Papizan Dolan Fellowship in Breast Oncology"},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s10637-020-00995-2","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:02:33Z","timestamp":1601251353000},"page":"509-515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer"],"prefix":"10.1007","volume":"39","author":[{"given":"Clinton","family":"Yam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaiane M.","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanbin","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Karuturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ravenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Clayborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sausan","family":"Abouharb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Litton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Stec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Fraser","family":"Symmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Damodaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy L.","family":"Moulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"issue":"10","key":"995_CR1","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-10-0644","volume":"9","author":"M Lopus","year":"2010","unstructured":"Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R, Jordan MA (2010) Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 9(10):2689\u20132699. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0644","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"995_CR2","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","volume":"14","author":"O Ab","year":"2015","unstructured":"Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J, Goldmacher VS, Chittenden T, Lambert JM (2015) IMGN853, a Folate Receptor-alpha (FRalpha)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRalpha-Expressing Tumors. Mol Cancer Ther 14(7):1605\u20131613. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-1095","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"995_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1021\/bc900315y","volume":"21","author":"HK Erickson","year":"2010","unstructured":"Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, Singh R (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 21(1):84\u201392. https:\/\/doi.org\/10.1021\/bc900315y","journal-title":"Bioconjug Chem"},{"issue":"16","key":"995_CR4","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1002\/cncr.30736","volume":"123","author":"KN Moore","year":"2017","unstructured":"Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ (2017) Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors. Cancer 123(16):3080\u20133087. https:\/\/doi.org\/10.1002\/cncr.30736","journal-title":"Cancer"},{"issue":"4","key":"995_CR5","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/cncr.22836","volume":"110","author":"GJ Morris","year":"2007","unstructured":"Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's surveillance, epidemiology, and end results database. Cancer 110(4):876\u2013884. https:\/\/doi.org\/10.1002\/cncr.22836","journal-title":"Cancer"},{"issue":"1\u20132","key":"995_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3121\/cmr.2009.825","volume":"7","author":"AA Onitilo","year":"2009","unstructured":"Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER\/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7(1\u20132):4\u201313. https:\/\/doi.org\/10.3121\/cmr.2009.825","journal-title":"Clin Med Res"},{"issue":"9","key":"995_CR7","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.22618","volume":"109","author":"KR Bauer","year":"2007","unstructured":"Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 109(9):1721\u20131728. https:\/\/doi.org\/10.1002\/cncr.22618","journal-title":"Cancer"},{"issue":"1","key":"995_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/modpathol.2009.145","volume":"23","author":"AA Thike","year":"2010","unstructured":"Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH (2010) Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 23(1):123\u2013133. https:\/\/doi.org\/10.1038\/modpathol.2009.145","journal-title":"Mod Pathol"},{"issue":"9","key":"995_CR9","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1634\/theoncologist.2017-0095","volume":"22","author":"C Yam","year":"2017","unstructured":"Yam C, Mani SA, Moulder SL (2017) Targeting the molecular subtypes of triple negative breast Cancer: understanding the diversity to Progress the field. Oncologist 22(9):1086\u20131093. https:\/\/doi.org\/10.1634\/theoncologist.2017-0095","journal-title":"Oncologist"},{"issue":"15 Pt 1","key":"995_CR10","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429\u20134434. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045","journal-title":"Clin Cancer Res"},{"issue":"8","key":"995_CR11","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","volume":"13","author":"LA Carey","year":"2007","unstructured":"Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329\u20132334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1109","journal-title":"Clin Cancer Res"},{"issue":"36","key":"995_CR12","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","volume":"24","author":"BG Haffty","year":"2006","unstructured":"Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652\u20135657. https:\/\/doi.org\/10.1200\/JCO.2006.06.5664","journal-title":"J Clin Oncol"},{"issue":"10","key":"995_CR13","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","volume":"35","author":"WF Symmans","year":"2017","unstructured":"Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN (2017) Long-term prognostic risk after Neoadjuvant chemotherapy associated with residual Cancer burden and breast Cancer subtype. J Clin Oncol 35(10):1049\u20131060. https:\/\/doi.org\/10.1200\/JCO.2015.63.1010","journal-title":"J Clin Oncol"},{"issue":"7","key":"995_CR14","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.clbc.2017.03.007","volume":"17","author":"PS Ginter","year":"2017","unstructured":"Ginter PS, McIntire PJ, Cui X, Irshaid L, Liu Y, Chen Z, Shin SJ (2017) Folate receptor alpha expression is associated with increased risk of recurrence in triple-negative breast Cancer. Clin Breast Cancer 17(7):544\u2013549. https:\/\/doi.org\/10.1016\/j.clbc.2017.03.007","journal-title":"Clin Breast Cancer"},{"key":"995_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41523-020-0147-1","volume":"6","author":"N Norton","year":"2020","unstructured":"Norton N, Youssef B, Hillman DW, Nassar A, Geiger XJ, Necela BM, Liu H, Ruddy KJ, Polley MC, Ingle JN, Couch FJ, Perez EA, Liu MC, Carter JM, Leon-Ferre RA, Boughey JC, Somers EB, Kalari KR, Visscher DW, Goetz MP, Knutson KL (2020) Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. NPJ Breast Cancer 6:4. https:\/\/doi.org\/10.1038\/s41523-020-0147-1","journal-title":"NPJ Breast Cancer"},{"issue":"20","key":"995_CR16","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1158\/1078-0432.CCR-18-0652","volume":"24","author":"A Cheung","year":"2018","unstructured":"Cheung A, Opzoomer J, Ilieva KM, Gazinska P, Hoffmann RM, Mirza H, Marlow R, Francesch-Domenech E, Fittall M, Dominguez Rodriguez D, Clifford A, Badder L, Patel N, Mele S, Pellizzari G, Bax HJ, Crescioli S, Petranyi G, Larcombe-Young D, Josephs DH, Canevari S, Figini M, Pinder S, Nestle FO, Gillett C, Spicer JF, Grigoriadis A, Tutt ANJ, Karagiannis SN (2018) Anti-Folate receptor alpha-directed antibody therapies restrict the growth of triple-negative breast Cancer. Clin Cancer Res 24(20):5098\u20135111. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0652","journal-title":"Clin Cancer Res"},{"issue":"7","key":"995_CR17","doi-asserted-by":"publisher","first-page":"890","DOI":"10.5858\/arpa.2013-0309-OA","volume":"138","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Wang J, Tacha DE, Li P, Bremer RE, Chen H, Wei B, Xiao X, Da J, Skinner K, Hicks DG, Bu H, Tang P (2014) Folate receptor alpha associated with triple-negative breast cancer and poor prognosis. Arch Pathol Lab Med 138(7):890\u2013895. https:\/\/doi.org\/10.5858\/arpa.2013-0309-OA","journal-title":"Arch Pathol Lab Med"},{"key":"995_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/2193-1801-1-22","volume":"1","author":"DJ O'Shannessy","year":"2012","unstructured":"O'Shannessy DJ, Somers EB, Maltzman J, Smale R, Fu YS (2012) Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. Springerplus 1:22. https:\/\/doi.org\/10.1186\/2193-1801-1-22","journal-title":"Springerplus"},{"issue":"8","key":"995_CR19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.addr.2004.01.001","volume":"56","author":"H Elnakat","year":"2004","unstructured":"Elnakat H, Ratnam M (2004) Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 56(8):1067\u20131084. https:\/\/doi.org\/10.1016\/j.addr.2004.01.001","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"995_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10555-007-9048-0","volume":"26","author":"MD Salazar","year":"2007","unstructured":"Salazar MD, Ratnam M (2007) The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 26(1):141\u2013152. https:\/\/doi.org\/10.1007\/s10555-007-9048-0","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"995_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10549-018-4941-5","volume":"172","author":"ED Frontera","year":"2018","unstructured":"Frontera ED, Khansa RM, Schalk DL, Leakan LE, Guerin-Edbauer TJ, Ratnam M, Gorski DH, Speyer CL (2018) IgA fc-folate conjugate activates and recruits neutrophils to directly target triple-negative breast cancer cells. Breast Cancer Res Treat 172(3):551\u2013560. https:\/\/doi.org\/10.1007\/s10549-018-4941-5","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"995_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"995_CR23","doi-asserted-by":"publisher","first-page":"v403","DOI":"10.1093\/annonc\/mdz250","volume":"30","author":"K Moore","year":"2019","unstructured":"Moore K, Oza A, Colombo N, Oaknin A, Scambia G, Lorusso D, Farias-Eisner R, Banerjee S, Murphy C, Tanyi J, Hirte H, Konner J, Lim P, Hayes M, Monk B, Kim S, Wang J, Pautier P, Vergote I, Birrer M (2019) 992OFORWARD I (GOG 3011): a phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC). Ann Oncol 30:v403. https:\/\/doi.org\/10.1093\/annonc\/mdz250","journal-title":"Ann Oncol"},{"issue":"2","key":"995_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","volume":"147","author":"LP Martin","year":"2017","unstructured":"Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ (2017) Characterization of folate receptor alpha (FRalpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FRalpha-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol 147(2):402\u2013407. https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.015","journal-title":"Gynecol Oncol"},{"issue":"9","key":"995_CR25","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1021\/acs.molpharmaceut.9b00653","volume":"16","author":"GS Heo","year":"2019","unstructured":"Heo GS, Detering L, Luehmann HP, Primeau T, Lee YS, Laforest R, Li S, Stec J, Lim KH, Lockhart AC, Liu Y (2019) Folate receptor alpha-targeted (89)Zr-M9346A Immuno-PET for image-guided intervention with Mirvetuximab Soravtansine in triple-negative breast Cancer. Mol Pharm 16(9):3996\u20134006. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00653","journal-title":"Mol Pharm"},{"issue":"10","key":"995_CR26","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","volume":"35","author":"KN Moore","year":"2017","unstructured":"Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ (2017) Safety and activity of Mirvetuximab Soravtansine (IMGN853), a Folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal Cancer: a phase I expansion study. J Clin Oncol 35(10):1112\u20131118. https:\/\/doi.org\/10.1200\/JCO.2016.69.9538","journal-title":"J Clin Oncol"},{"issue":"1","key":"995_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ygyno.2018.07.017","volume":"151","author":"KN Moore","year":"2018","unstructured":"Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ (2018) Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol 151(1):46\u201352. https:\/\/doi.org\/10.1016\/j.ygyno.2018.07.017","journal-title":"Gynecol Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00995-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00995-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00995-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:57:05Z","timestamp":1678510625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00995-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["995"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00995-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,28]]},"assertion":[{"value":"15 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"J.K.L. has received grant or research support from Novartis, Medivation\/Pfizer, Genentech, GSK, EMD-Serono, Astra-Zeneca, Medimmune, Zenith, Jounce; participated in Speaker\u2019s Bureau for MedLearning, Physician\u2019s Education Resource, Prime Oncology, Medscape, Clinical Care Options; received honoraria from UpToDate; served on advisory committees or review panels for Astra-Zeneca, Ayala, Pfizer (all uncompensated), NCCN, ASCO, NIH, PDQ, SITC Breast Committee, SWOG Breast Committee. J.S. is a full-time employee and shareholder of ImmunoGen, Inc. S.L.M. has received research support from the NCCN for the clinical trial. All other authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}